King Trumpet and Cancer: Antitumor Research

King Oyster Mushroom

4 cancer types studied with Pleurotus eryngii compounds

Renal cancer, hepatoma, colon cancer, and breast cancer have each been studied with Pleurotus eryngii compounds in separate preclinical research programs. Multiple compound classes show activity: polysaccharides, a specific tumor-inhibiting protein (PEP), a mycelium polypeptide, and a triterpene. No human clinical trials exist.

Yang 2013; Ren 2016; Yuan 2017; Xue 2015

PEP protein

a specific protein from P. eryngii fruiting bodies that inhibited colon cancer cell growth in both cell culture and live mice (Yuan et al., 2017)

Triterpene + MCF-7

a triterpene isolated from P. eryngii showed inhibitory effects on MCF-7 breast cancer cells in vitro (Xue et al., 2015)

All preclinical

every P. eryngii cancer study is in vitro or in animal models; there are no human clinical trials on king trumpet for cancer

Yang 2013; Ren 2016; Yuan 2017; Xue 2015

View as image ↗

King trumpet (Pleurotus eryngii) is less studied for cancer than turkey tail (which has FDA-reviewed clinical trial data and Japanese drug approval), reishi (which has multiple human adjuvant trials), or shiitake (with lentinan approved in Japan). That comparison establishes the honest starting point: king trumpet's cancer research is earlier-stage and preclinical. What exists is a body of cell culture and animal model studies covering four cancer types through multiple independent compound classes, suggesting that king trumpet's antitumor potential may be broader than its current research profile reflects.

This article maps what the research shows, compound by compound and cancer type by cancer type, with honest assessment of what preclinical evidence can and cannot tell us. For clinical-grade cancer mushroom research, see how king trumpet compares to PSK: the most successful mushroom-derived drug and what is king trumpet mushroom: the meaty mushroom with health benefits.

Where King Trumpet Stands in Mushroom Cancer Research

The mushroom-cancer research landscape has clear tiers. Turkey tail's PSK is a licensed cancer adjuvant drug in Japan with decades of clinical trial data. Reishi has multiple human adjuvant trials showing effects on immune recovery during chemotherapy. Lentinan from shiitake is a separate approved drug in Japan for gastric cancer.

King trumpet is at an earlier stage: the preclinical evidence exists across multiple cancer types and compound classes, but the transition from cell culture and animal models to human clinical trials has not occurred for any P. eryngii cancer indication.

This is not unusual. Most of the mushrooms with strong clinical evidence went through decades of preclinical investigation before clinical development. King trumpet's compound map is interesting enough to warrant attention, and its preclinical evidence covers more cancer types and compound diversity than most non-clinical mushroom profiles. But the absence of human trials means the practical significance for cancer prevention or treatment remains unestablished.

A 2020 systematic review by Chen and colleagues reviewed mushroom extracts and compounds for breast cancer activity across cell culture, mouse, and rat studies, providing class-level context for where P. eryngii's breast cancer data fits within broader mushroom research.^[6] The review confirmed that multiple mushroom species, including Pleurotus species, show consistent breast cancer cell activity in cell models.

Polysaccharides and Renal Cancer

Yang and colleagues (2013) tested a polysaccharide purified from P. eryngii in mice bearing renal (kidney) cancer tumors.^[1]

The polysaccharide significantly inhibited tumor growth in the treated mice compared to untreated controls. Beyond direct tumor inhibition, the treated mice showed improvements in immune function markers, suggesting that the antitumor effect was at least partly mediated through immune activation rather than direct tumor cell toxicity alone.

This immune-mediated mechanism is consistent with how many mushroom polysaccharides are thought to produce antitumor effects: by activating or restoring immune surveillance that helps the body identify and eliminate cancer cells, rather than directly poisoning the tumor (as conventional chemotherapy does). The distinction matters because immune-mediated effects may complement rather than compete with conventional cancer treatments.

Polysaccharides and Liver Cancer

Ren and colleagues (2016) chemically characterized a polysaccharide from P. eryngii and tested its effects on HepG-2 cells, a human hepatoblastoma (liver cancer) cell line.^[2]

The polysaccharide induced apoptosis (programmed cell death) in HepG-2 cells through activation of the intrinsic mitochondrial apoptosis pathway. This pathway is a common target in cancer research because cancer cells often have suppressed apoptosis, allowing them to survive longer than they should. Compounds that reactivate this pathway cause cancer cells to undergo the death process they have evaded.

Ren's work provided both a structural characterization of the active polysaccharide (establishing what it is chemically) and a mechanistic explanation for how it kills cancer cells (which pathway it activates). This level of specificity is important for evaluating the research quality: the finding is not just "extract killed cancer cells" but "specific characterized compound activates mitochondrial apoptosis pathway."

PEP Protein: Colon Cancer In Vitro and In Vivo

Yuan and colleagues (2017) isolated a specific protein from P. eryngii fruiting bodies, designated PEP (Pleurotus eryngii protein), and tested it against colon cancer through both cell culture and live animal studies.^[3]

This study is particularly notable because it used both in vitro (cell culture) and in vivo (live mice bearing colon tumors) models, providing two independent levels of evidence for the same compound. In vitro, PEP inhibited colon cancer cell growth. In vivo, mice bearing colon tumors that received PEP showed reduced tumor growth compared to controls.

The in vivo validation matters because many compounds that kill cancer cells in a dish fail to produce effects in living animals, where pharmacokinetics (absorption, distribution, metabolism, excretion) determine whether enough compound reaches the tumor in active form. PEP passing the in vivo test is a meaningful progression from purely in vitro data.

The mechanism involved inhibition of cell proliferation and induction of cell cycle arrest, preventing the cancer cells from continuing to divide.

Mycelium Polypeptide: Three Functions in One

Sun and colleagues (2017) investigated a polypeptide (PEMP) from P. eryngii mycelium and documented three simultaneous biological activities: antioxidant activity, antitumor activity against cancer cells, and immunostimulatory effects on immune cell populations.^[4]

The mycelium compound data is relevant beyond just adding to the cancer evidence base. It documents that P. eryngii mycelium contains bioactive compounds distinct from those in the fruiting body. Most consumer products use fruiting body material; the mycelium research represents a separate compound pool that commercial product development could access.

The combination of antitumor and immunostimulatory activity in a single compound is consistent with the mechanism seen in Yang's renal cancer study: mushroom compounds may be doing double duty, directly inhibiting some cancer cell processes while also enhancing the immune response that identifies and destroys cancer cells.

Triterpene and Breast Cancer

Xue and colleagues (2015) structurally identified a triterpene from P. eryngii and tested it against MCF-7 cells, a widely used breast cancer cell line.^[5]

Triterpenes are lipid-soluble compounds (unlike polysaccharides, which are water-soluble). King trumpet's triterpene profile is distinct from reishi's large triterpene library, but the structural identification by Xue and colleagues established that P. eryngii contains at least one triterpene with anti-cancer cell activity.

The MCF-7 cell model is one of the most studied breast cancer cell lines, making Xue's finding directly comparable to the large breast cancer literature on other mushroom extracts. Chen et al.'s 2020 systematic review of mushroom compounds for breast cancer placed P. eryngii's data within this broader landscape.^[6]

The Evidence Map: Four Cancer Types, Multiple Compounds

Taken together, the king trumpet cancer research covers a broader landscape than most single-mushroom cancer studies:

No single compound shows activity across all cancer types, and no study has tested the same compound in multiple cancer models. The breadth comes from multiple independent research groups testing different extracted fractions on different cancer targets.

What This Evidence Means Practically

King trumpet is a nutritionally valuable food with documented bioactive compounds. Its antitumor activity in preclinical models provides a mechanistic rationale for its potential contribution to a health-supporting diet. It does not provide evidence that eating king trumpet prevents or treats cancer in humans.

The gap between preclinical and clinical evidence in cancer research is substantial. Many compounds that kill cancer cells in culture or slow tumor growth in mice fail to show clinical benefit in human trials, due to differences in pharmacokinetics, immune context, and the complexity of human cancer biology.

King trumpet should not replace conventional cancer treatment. If someone with cancer is considering mushroom supplements as part of their dietary approach, a conversation with their oncologist is appropriate to address any potential interactions with treatment.

The Bottom Line

King trumpet mushroom (Pleurotus eryngii) has documented antitumor activity in preclinical models across four cancer types through multiple compound classes: polysaccharides showing activity in renal cancer in vivo (Yang et al., 2013) and hepatoma in vitro (Ren et al., 2016); PEP protein showing colon cancer inhibition both in vitro and in vivo (Yuan et al., 2017); PEMP mycelium polypeptide with antioxidant, antitumor, and immunostimulatory activity (Sun et al., 2017); and a structurally identified triterpene showing breast cancer MCF-7 cell inhibition (Xue et al., 2015). No human clinical trial has been conducted on king trumpet for any cancer indication. King trumpet is earlier-stage in cancer research than turkey tail, reishi, or shiitake, which have human clinical data.

Frequently Asked Questions

Does king trumpet mushroom have anti-cancer properties?

King trumpet mushroom (Pleurotus eryngii) contains compounds with demonstrated anti-cancer activity in preclinical research: polysaccharides inhibit renal cancer in mice and hepatoma cells; a specific protein (PEP) inhibits colon cancer in vitro and in vivo; a mycelium polypeptide shows antitumor activity; and a triterpene inhibits breast cancer MCF-7 cells. All evidence is preclinical (cell culture or animal models); no human clinical trials have been conducted on P. eryngii for any cancer indication.

Is king oyster mushroom good for cancer?

King oyster mushroom has antitumor activity in laboratory models for renal, liver, colon, and breast cancer cells, mediated through polysaccharides, specific proteins, polypeptides, and triterpenes. However, all of this evidence is from cell culture studies and animal experiments, not human clinical trials. King oyster is a nutritionally valuable food, but it should not replace conventional cancer treatment. Turkey tail (with PSK drug approval in Japan) has substantially more clinical evidence for cancer-adjacent applications.

What compounds in king trumpet mushroom fight cancer?

Multiple compound classes have demonstrated anti-cancer activity in laboratory research: polysaccharides (water-soluble, inhibit renal and liver cancer cells through immune activation and apoptosis pathways); PEP protein (a specific fruiting body protein with colon cancer activity); PEMP polypeptide from mycelium (antitumor and immunostimulatory); and a structurally identified triterpene with breast cancer cell inhibition. The compounds operate through different mechanisms, suggesting king trumpet's antitumor activity is not from a single compound but from several acting independently.

Is there research on Pleurotus eryngii and cancer?

Yes. Published peer-reviewed studies on P. eryngii and cancer include: Yang et al. (2013) on renal cancer in mice; Ren et al. (2016) on hepatoblastoma cell apoptosis; Yuan et al. (2017) on colon cancer in both cell culture and animal models; Sun et al. (2017) on mycelium polypeptide antitumor activity; and Xue et al. (2015) on triterpene inhibition of breast cancer MCF-7 cells. Chen et al. (2020) placed the breast cancer findings within a broader systematic review of mushroom compounds for breast cancer.

What types of cancer has king trumpet mushroom been studied for?

Renal (kidney) cancer in animal models (Yang et al., 2013); hepatoblastoma (liver cancer) in cell culture (Ren et al., 2016); colon cancer in both cell culture and mice (Yuan et al., 2017); and breast cancer in cell culture (Xue et al., 2015). Multiple compound classes from different extraction methods have been tested, suggesting the anti-cancer activity reflects multiple independent mechanisms rather than a single dominant compound. Prostate cancer and other types have limited or no P. eryngii-specific data.

Sources & References

1. 1. Source details for this reference are not yet available.
2. 2. Source details for this reference are not yet available.
3. 3. Source details for this reference are not yet available.
4. 4. Source details for this reference are not yet available.
5. 5. Source details for this reference are not yet available.
6. 6. Source details for this reference are not yet available.
7. 7. Source details for this reference are not yet available.